Ignite Creation Date:
2025-12-25 @ 1:37 AM
Ignite Modification Date:
2026-05-27 @ 2:13 PM
Study NCT ID:
NCT00299494
Status:
COMPLETED
Last Update Posted:
2018-03-08
First Post:
2006-03-02
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
Sponsor:
Pfizer
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
3129K3-101
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |